In conclusion, we show here that a sizable fraction of DLBCL patients, especially of the ABC subtype, exhibit hallmarks of aberrant activation of the IL‐6 signaling pathway which constitutes a promising therapeutic target in this population. This evidence concerns the gene IL6 and diffuse large B-cell lymphoma.